PF-02341066, a brand new drug to treat advanced non-small cell lung cancer, from Pfizer will soon go for Phase 3 clinical studies.PF-02341066 is an oral c-Met and ALK inhibitor. PF-02341066‘s Phase 3 clinical trial versus normal of care chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) carrying the ALK (anaplastic lymphoma kinases) fusion
(Read More…)
Husain H, Rudin CM. “ONCOLOGY-NEW YORK JUN 2011″ Lung cancer remains the major cause of cancer-related dying within the United states. Ongoing analysis into the molecular basis of lung cancer has yielded perception into different crucial pathways that are deregulated in lung tumorigenesis, and in certain key driver mutations integral to cancer cell survival and
(Read More…)
Follow @selleckchem on twitter.
